Curis (NASDAQ:CRIS) Share Price Passes Above Two Hundred Day Moving Average of $10.73

Curis, Inc. (NASDAQ:CRIS - Get Free Report) shares crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $10.73 and traded as high as $15.27. Curis shares last traded at $15.27, with a volume of 22,370 shares changing hands.

Analyst Upgrades and Downgrades

Separately, HC Wainwright dropped their target price on shares of Curis from $51.00 to $26.00 and set a "buy" rating on the stock in a research report on Friday, February 9th.

Curis Stock Performance

The company has a market cap of $93.95 million, a price-to-earnings ratio of -1.75 and a beta of 3.72. The firm's 50 day simple moving average is $11.38 and its 200-day simple moving average is $9.91.

Curis (NASDAQ:CRIS - Get Free Report) last announced its quarterly earnings data on Thursday, February 8th. The biotechnology company reported ($2.03) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.91) by ($0.12). Curis had a negative net margin of 473.04% and a negative return on equity of 169.22%. The business had revenue of $2.70 million for the quarter, compared to analysts' expectations of $2.95 million. During the same period in the prior year, the company posted ($2.40) EPS. As a group, sell-side analysts expect that Curis, Inc. will post -5.92 EPS for the current fiscal year.

Hedge Funds Weigh In On Curis

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Jacobs Levy Equity Management Inc. purchased a new stake in shares of Curis during the 3rd quarter valued at approximately $948,000. Renaissance Technologies LLC increased its stake in Curis by 81.5% during the second quarter. Renaissance Technologies LLC now owns 2,392,035 shares of the biotechnology company's stock worth $2,355,000 after acquiring an additional 1,073,835 shares during the last quarter. Walleye Capital LLC raised its position in Curis by 3,036.1% in the first quarter. Walleye Capital LLC now owns 841,793 shares of the biotechnology company's stock valued at $2,003,000 after purchasing an additional 814,951 shares during the period. BNP Paribas Arbitrage SA lifted its stake in shares of Curis by 465.8% in the 1st quarter. BNP Paribas Arbitrage SA now owns 446,469 shares of the biotechnology company's stock valued at $1,063,000 after purchasing an additional 367,559 shares during the last quarter. Finally, BlackRock Inc. lifted its stake in shares of Curis by 4.9% in the 1st quarter. BlackRock Inc. now owns 6,587,381 shares of the biotechnology company's stock valued at $15,677,000 after purchasing an additional 306,340 shares during the last quarter. Institutional investors and hedge funds own 29.97% of the company's stock.

Curis Company Profile

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.